Double-blind, Placebo-controlled Clinical Trial of JK6476 (Risperidone) in Patients With Hallucinations and Delusions Associated With Alzheimer's Disease.

Trial Profile

Double-blind, Placebo-controlled Clinical Trial of JK6476 (Risperidone) in Patients With Hallucinations and Delusions Associated With Alzheimer's Disease.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2010

At a glance

  • Drugs Risperidone (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Janssen
  • Most Recent Events

    • 12 Nov 2010 Actual end date (Mar 2003) added as reported by ClinicalTrials.gov.
    • 12 Nov 2010 Actual initiation date (Mar 2002) added as reported by ClinicalTrials.gov.
    • 09 May 2008 Status changed from in progress to discontinued according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top